Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year.

Autor: Mangia PP; AdRes Health Economics and Outcome Research, Via Alfieri 17, 10121, Turin, Italy., Gallo O; Novartis Farma, Origgio (VA), Italy., Ritrovato D; Novartis Farma, Origgio (VA), Italy., Pradelli L; AdRes Health Economics and Outcome Research, Via Alfieri 17, 10121, Turin, Italy. l.pradelli@adreshe.com.

Publikováno v: Clinical drug investigation [Clin Drug Investig] 2021 Sep; Vol. 41 (9), pp. 785-794. Date of Electronic Publication: 2021 Jul 31.